

WHAT IS CLAIMED IS:

- 1 1. A method for determining whether a subject has or is predisposed for a
2 mental disorder, the method comprising the steps of:
 - 3 (i) obtaining a biological sample from a subject;
 - 4 (ii) contacting the sample with a reagent that selectively associates with a
5 polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent
6 conditions to a nucleotide sequence of SEQ ID NO:1 or 3; and
 - 7 (iii) detecting the level of reagent that selectively associates with the sample,
8 thereby determining whether the subject has or is predisposed for a mental disorder.
- 1 2. The method of claim 1, wherein the reagent is an antibody.
- 1 3. The method of claim 1, wherein the reagent is a nucleic acid.
- 1 4. The method of claim 1, wherein the reagent associates with a
2 polynucleotide.
- 1 5. The method of claim 1, wherein the reagent associates with a
2 polypeptide.
- 1 6. The method of claim 1, wherein the level of reagent that associates
2 with the sample is different from a level associated with humans without a mental disorder.
- 1 7. The method of claim 1, wherein the biological sample is obtained from
2 amniotic fluid.
- 1 8. The method of claim 1, wherein the mental disorder is a mood disorder
2 or psychosis.
- 1 9. The method of claim 7, wherein the mood disorder is selected from the
2 group consisting of bipolar disorder and major depression.
- 1 10. The method of claim 8, wherein the psychosis is schizophrenia.
- 1 11. The method of claim 1, wherein the polynucleotide comprises a
2 nucleotide sequence of SEQ ID NO:1 or 3.

- 1 12. The method of claim 1, wherein the polypeptide comprises an amino
2 acid sequence of SEQ ID NO:2 or 4.
- 1 13. A method of identifying a compound for treatment of a mental
2 disorder, the method comprising the steps of:
3 (i) contacting the compound with a polypeptide, the polypeptide encoded by a
4 polynucleotide that hybridizes under stringent conditions to a nucleic acid sequence
5 comprising a nucleotide sequence of SEQ ID NO:1 or 3; and
6 (ii) determining the functional effect of the compound upon the polypeptide,
7 thereby identifying a compound for treatment of a mental disorder.
- 1 14. The method of claim 13, wherein the contacting step is performed *in*
2 *vitro*.
- 1 15. The method of claim 13, wherein the polypeptide is expressed in a cell
2 and the cell is contacted with the compound.
- 1 16. The method of claim 13, wherein the mental disorder is a mood
2 disorder or psychosis.
- 1 17. The method of claim 16, wherein the mood disorder is selected from
2 the group consisting of bipolar disorder and major depression.
- 1 18. The method of claim 16, wherein the psychosis is schizophrenia.
- 1 19. The method of claim 18, further comprising administering the
2 compound to an animal and determining the effect on the animal.
- 1 20. The method of claim 19, wherein the determining step comprises
2 testing the animal's mental function.
- 1 21. The method of claim 13, wherein the polynucleotide comprising a
2 nucleotide sequence of SEQ ID NO:1 or 3.
- 1 22. The method of claim 13, wherein the polypeptide comprises an amino
2 acid sequence of SEQ ID NO:2 or 4.

- 1 23. A method of identifying a compound for treatment of a mental disorder
2 in a subject, the method comprising the steps of:
3 (i) contacting the compound to a cell, the cell comprising a polynucleotide that
4 hybridizes under stringent conditions to a nucleotide sequence of SEQ ID NO:1 or 3; and
5 (ii) selecting a compound that modulates expression of the polynucleotide,
6 thereby identifying a compound for treatment of a mental disorder.
- 1 24. The method of claim 23, wherein the expression of the polynucleotide
2 is enhanced.
- 1 25. The method of claim 23, wherein the expression of the polynucleotide
2 is decreased.
- 1 26. The method of claim 23, further comprising administering the
2 compound to an animal and determining the effect on the animal.
- 1 27. The method of claim 26, wherein the determining step comprises
2 testing the animal's mental function.
- 1 28. The method of claim 23, wherein the mental disorder is a mood
2 disorder or psychosis.
- 1 29. The method of claim 28, wherein the mood disorder is selected from
2 the group consisting of bipolar disorder and major depression.
- 1 30. The method of claim 28, wherein the psychosis is schizophrenia.
- 1 31. The method of claim 23, wherein the polynucleotide comprises a
2 nucleotide sequence of SEQ ID NO:1 or 3.
- 1 32. A method of treating a mental disorder in a subject, the method
2 comprising the step of administering to the subject a therapeutically effective amount of a
3 compound identified using the method of claim 13 or claim 23.
- 1 33. The method of claim 32, wherein the mental disorder is a mood
2 disorder or psychosis.

- 1 34. The method of claim 33, wherein the mood disorder is selected from
2 the group consisting of bipolar disorder and major depression.
- 1 35. The method of claim 33, wherein the psychosis is schizophrenia.
- 1 36. The method of claim 32, wherein the compound is a nucleic acid.
- 1 37. The method of claim 36, wherein the nucleic acid hybridizes under
2 stringent conditions to a nucleic acid comprising a nucleotide sequence of SEQ ID NO:1 or 3.
- 1 38. The method of claim 32, wherein the compound is identified using the
2 method of claim 14 and the polynucleotide comprises a nucleotide sequence of SEQ ID NO:1
3 or 3.
- 1 39. The method of claim 32, wherein the compound is identified using the
2 method of claim 14 and the polypeptide comprises an amino acid sequence of SEQ ID NO:2
3 or 4.
- 1 40. The method of claim 32, wherein the compound is identified using the
2 method of claim 24 and the polynucleotide comprises a nucleotide sequence of SEQ ID NO:
3 1 or 3.
- 1 41. A method of treating mental illness in a subject, the method
2 comprising the step of administering to the subject a therapeutically effective amount of a
3 polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent
4 conditions to a nucleotide sequence of SEQ ID NO:1 or 3.
- 1 42. The method of claim 41, wherein the polynucleotide comprises a
2 nucleotide sequence of SEQ ID NO:1 or 3.
- 1 43. The method of claim 41, wherein the mental illness is a mood disorder
2 or psychosis.
- 1 44. The method of claim 43, wherein the mood disorder is selected from
2 the group consisting of bipolar disorder and major depression.
- 1 45. The method of claim 43, wherein the psychosis is schizophrenia.

1 46. A method of treating mental illness in a subject, the method
2 comprising the step of administering to the subject a therapeutically effective amount of a
3 nucleic acid, wherein the nucleic acid hybridizes under stringent conditions to a nucleotide
4 sequence of SEQ ID NO:1 or 3.

1 47. The method of claim 46, wherein the mental illness is a mood disorder
2 or psychosis.

1 48. The method of claim 47, wherein the mood disorder is selected from
2 the group consisting of bipolar disorder and major depression.

1 49. The method of claim 47, wherein the psychosis is schizophrenia.

1 50. The method of claim 46, wherein the nucleic acid comprises a
2 complementary sequence to the nucleotide sequence of SEQ ID NO:1 or 3.